Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials.

British Journal of Cancer
Namrata VijayvergiaJonathan R Strosberg

Abstract

Metastatic high-grade neuroendocrine neoplasms (G3NENs) have limited treatment options after progression on platinum-based therapy. We addressed the role of Pembrolizumab in patients with previously treated metastatic G3NENs. Two open-label, phase 2 studies enrolled patients with G3NEN (Ki-67 > 20%) to receive Pembrolizumab at 200 mg I.V. every 3 weeks. Radiographic evaluation was conducted every 9 weeks with overall response rate as the primary endpoint. Between November 2016 and May 2018, 29 patients (13 males/16 females) with G3NENs were enrolled. One patient (3.4%) had an objective response and an additional six patients (20.7%) had stable disease, resulting in a disease control rate of 24.1%. Disease control rate (DCR) at 18 weeks was 10.3% (3/29). There was no difference in the DCR, PFS or OS between the PD-L1-negative and -positive groups (p 0.56, 0.88 and 0.55, respectively). Pembrolizumab was well tolerated with only 9 grade 3, and no grade 4 events considered drug-related. Pembrolizumab can be safely administered to patients with G3NENs but has limited activity as a single agent. Successful completion of our trials suggest studies in G3NENs are feasible and present an unmet need. Further research to identify active co...Continue Reading

References

May 1, 1997·Cancer·E GalanisR V Lloyd
Jun 21, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James C YaoDouglas B Evans
Dec 11, 2008·Cancer Treatment Reviews·Annemiek M E WalenkampDirk T Sleijfer
Nov 26, 2010·Endocrinology and Metabolism Clinics of North America·Guido RindiEnrico Solcia
Sep 13, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H SorbyeU Knigge
Sep 14, 2012·TheScientificWorldJournal·Ingrid H OlsenSeppo W Langer
Jun 4, 2013·The New England Journal of Medicine·Omid HamidAntoni Ribas
Jun 4, 2013·The New England Journal of Medicine·Jedd D WolchokMario Sznol
Jul 13, 2013·Endocrine-related Cancer·Fritz-Line Vélayoudom-CéphiseEric Baudin
Apr 29, 2014·Cancer·Halfdan SorbyeJames C Yao
Nov 20, 2014·The New England Journal of Medicine·Alexandra SnyderTimothy A Chan
Dec 3, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerHans J Hammers
Apr 29, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pamela L Kunz
Jun 2, 2015·The New England Journal of Medicine·Julie BrahmerDavid R Spigel
Jun 27, 2015·Endocrine-related Cancer·M HeetfeldUNKNOWN other Knowledge Network members
Mar 10, 2016·Journal of Cancer·Seung Tae KimYoung Suk Park
Oct 11, 2016·The New England Journal of Medicine·Martin ReckUNKNOWN KEYNOTE-024 Investigators
Jan 30, 2018·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Hye Sook KimJi-Youn Han
Aug 14, 2018·Endocrinology and Metabolism Clinics of North America·Frediano InzaniGuido Rindi
Feb 7, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paul NghiemSuzanne L Topalian
Jan 24, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sandip P PatelRazelle Kurzrock

❮ Previous
Next ❯

Citations

Sep 29, 2020·World Journal of Gastroenterology : WJG·Rani KanthanSelliah C Kanthan
Jun 2, 2020·World Journal of Gastroenterology : WJG·Zu-Yi MaBao-Hua Hou
Aug 31, 2020·World Journal of Gastrointestinal Oncology·Ming-Yi ZhangShuang Zhang
Sep 5, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Alberto PucciniHeinz-Josef Lenz
Feb 6, 2021·Endocrine·Anna KoumarianouKrystallenia I Alexandraki
Feb 10, 2021·Current Treatment Options in Oncology·Nicola Fazio, Omar Abdel-Rahman
Nov 5, 2020·Oncotarget·Taymeyah Al-ToubahJonathan Strosberg
Feb 9, 2021·Clinical Colorectal Cancer·Benjamin E UeberrothM Bassam Sonbol
Jan 6, 2021·Cancer Immunology, Immunotherapy : CII·Alexander W MacFarlaneNamrata Vijayvergia
Nov 19, 2020·Journal of Clinical Medicine·Mauro CivesJonathan Strosberg
May 1, 2021·Cancers·Anna La SalviaRocío Garcia-Carbonero
May 4, 2021·Current Oncology Reports·Victor Rodriguez-FreixinosSimron Singh
May 4, 2021·Pancreas·Jennifer J GileThorvardur R Halfdanarson
Jul 12, 2021·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Akihiro OhmotoShunji Takahashi
Aug 8, 2021·Cancers·Anna PellatRomain Coriat
Sep 3, 2021·Cancer Immunology, Immunotherapy : CII·Christo KoleDimitrios Schizas

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.